Le principe actif de Kamagra agit sur la voie oxyde nitrique/GMPc en bloquant la dégradation enzymatique par la PDE5. Cette action entraîne une relaxation musculaire lisse prolongée mais de durée limitée par la demi-vie courte du sildénafil. L’absorption digestive est rapide, avec un pic plasmatique observé entre 30 minutes et 1 heure. Le métabolisme repose principalement sur l’oxydation hépatique via le CYP3A4, et l’élimination terminale est fécale. Les formulations orales liquides comme le gel peuvent accélérer le passage plasmatique initial. Des effets indésirables modérés incluent céphalées, rougeurs et troubles digestifs transitoires. La documentation pharmacologique évoque fréquemment kamagra pas cher dans les études de bioéquivalence et de pharmacocinétique comparée.
Figo2009.org.za
XIX FIGO WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS INDUSTRY-SPONSORED SYMPOSIA Monday, 5 October 2009 13h00-14h15 Ballroom East (CTICC) Contraception and Beyond: Evidence-based Indications for LNG-IUS 1. Wider Use of Intrauterine Contraception - David Grimes
2. The LNG-IUS in Heavy Menstrual Bleeding: First-line Treatment Based on Comprehensive Clinical Data - Anita Nelson
3. Safety and Efficacy of Consecutive Use of the LNG-IUS - Confirmed by a New Study -Kristina Gemzell-Danielsson
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) The Role of GARDASIL™ in Reducing the Global Burden of Cervical Cancer and Other HPV-Related Diseases 1. Opening Remarks – Lynette Denny, South Africa
2. Global HPV Epidemiology and Burden of Disease - Lynette Denny, South Africa3. Gardasil Efficacy and Recent Clinical Data - Suzanne M. Garland, Australia
4. MSD’s Commitment: Access to Gardasil in the Developing World - Carlos Sattler, USA
Symposium sponsored by MSD Tuesday, 6 October 2009 13h00-14h15 Ballroom East (CTICC) Innovation in Contraception 1. Ethinylestradiol 20mcg/Drospirenone 3mg Administered in a 24/4 Regimen: A New OC Goes Beyond Contraception - Joachim Marr and Lorraine Dennerstein
2. A New OC Concept with Additional Benefit - Wolfgang Holzgreve and Klaus Pietrzik
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Overactive Bladder: TIME to take notice Chairman’s Introduction
1. The Burden and Implications of OAB – Linda Cardozo, UK2. Initial Diagnosis and Assessment of Women with LUTS - Mickey Karram, USA3. Making Sure We Understand Our Patient’s Needs – Peter de Jong, South Africa
4. Ensuring Successful Management with Pharmacotherapy - Willy Davilla, USA
Symposium sponsored by Astellas Pharma Wednesday, 7 October 2009 13h00-14h15 Ballroom East (CTICC) Evolution of a Revolution: Introducing a New Class of Oral Contraceptive
1. Introducing E2V/DNG - Ian Fraser2. E2V/DNG: Contraceptive Efficacy and Safety Data - Jeffrey T. Jensen
3. First Experience with the Estradiol Based Combined Oral Contraceptive E2V/DNG - Diana Mansour
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Effective Solutions for Enhanced Obstetric Management 1. New Ultrasound Technologies in Assisted Reproductive Medicine SonoAVC - Nick Raine Fenning, Nottingham, UK
2. Enhancing the Monitoring Experience from Antepartum through to Postpartum - Philippe Barjot, Caen, France
3. Improving Obstetric Workflow, Archiving and Reporting - Philippe Barjot, Caen, France
Symposium sponsored by GE Healthcare Thursday, 8 October 2009 13h00-14h15 Ballroom East (CTICC) Improving Women's Healthcare - a Contemporary View Chair: Jennifer Blake 1. Progestins - An Important Versatile Class – Peter Rogers
2. Specialised Progestins I - Dienogest in Endometriosis - Alfred Mueck3. Specialised Progestins II – Drospirenone in Menopause - Tommaso Simoncini
Symposium sponsored by Bayer Schering Pharma Ballroom West (CTICC) Cervarix®: Focusing on the Global Needs of Cervical Cancer Vaccination 1. Welcome and Introduction – Anne Szarewski, UK and Hugues Bogaerts, Belgium
2. The Relevance of the HPV Type Distribution in Cervical Cancer – F. Xavier Bosch, Spain3. Understanding the Immunological Potential of HPV Vaccines – Peter L. Stern, UK4. Cervarix®: The Benefits to Girls and Women: From Clinical Trials to Clinical Practice – Anne
Symposium sponsored by GlaxoSmithKline
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors Learning Objectives After reading and reviewing this material, the participant should be better able to:• Identify symptoms of androgen deficiency in pre and post menopausal breast cancer survivors• Recognize the potential role of subcutaneous testosterone-anastrozole implant therapy in safely tr